These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 14733590

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Enhanced immunogenicity and cross-reactivity of HIV-1 V3-peptide and multiple antigen peptides conjugated to distinct carrier proteins.
    Cruz LJ, Cabrales A, Iglesias E, Aguilar JC, González LJ, Reyes O.
    Int Immunopharmacol; 2009 Nov; 9(12):1452-9. PubMed ID: 19747570
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Broader cross-reactivity after conjugation of V3 based multiple antigen peptides to HBsAg.
    Iglesias E, Aguilar JC, Cruz LJ, Reyes O.
    Mol Immunol; 2005 Jan; 42(1):99-104. PubMed ID: 15488948
    [Abstract] [Full Text] [Related]

  • 7. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE, Abaitua F, Rodríguez D, Esteban M.
    Virus Res; 2004 Sep 15; 105(1):11-22. PubMed ID: 15325077
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
    Hewer R, Meyer D.
    Vaccine; 2005 Mar 18; 23(17-18):2164-7. PubMed ID: 15755588
    [Abstract] [Full Text] [Related]

  • 10. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
    Shinoda K, Xin KQ, Jounai N, Kojima Y, Tamura Y, Okada E, Kawamoto S, Okuda K, Klinman D, Okuda K.
    Vaccine; 2004 Sep 09; 22(27-28):3676-90. PubMed ID: 15315847
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
    Megede JZ, Otten GR, Doe B, Liu H, Srivastava R, Greer C, Legg H, Tang T, Polo JM, Donnelly JJ, Ulmer JB, Barnett SW.
    Vaccine; 2006 Apr 05; 24(15):2755-63. PubMed ID: 16460840
    [Abstract] [Full Text] [Related]

  • 12. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
    Sheth HB, Glasier LM, Ellert NW, Cachia P, Kohn W, Lee KK, Paranchych W, Hodges RS, Irvin RT.
    Biomed Pept Proteins Nucleic Acids; 1995 Apr 05; 1(3):141-8. PubMed ID: 9346845
    [Abstract] [Full Text] [Related]

  • 13. Peptide based vaccine design: synthesis and immunological characterization of branched polypeptide conjugates comprising the 276-284 immunodominant epitope of HSV-1 glycoprotein D.
    Mezo G, Dalmadi B, Mucsi I, Bosze S, Rajnavölgyl E, Hudecz F.
    J Pept Sci; 2002 Mar 05; 8(3):107-17. PubMed ID: 11931583
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity evaluation of a lipidic amino acid-based synthetic peptide vaccine for Chlamydia trachomatis.
    Zhong G, Toth I, Reid R, Brunham RC.
    J Immunol; 1993 Oct 01; 151(7):3728-36. PubMed ID: 7690812
    [Abstract] [Full Text] [Related]

  • 15. [Composition of HIV-1 B-epitopes and heterologous T-cell epitopes. I. Maintenance of antigenic properties of HIV-1 B-epitopes].
    Isaguliants MG, Koshida R, Ruden U, Varen B.
    Biokhimiia; 1996 Jul 01; 61(7):1221-9. PubMed ID: 9035735
    [Abstract] [Full Text] [Related]

  • 16. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques.
    Egan MA, Chong SY, Hagen M, Megati S, Schadeck EB, Piacente P, Ma BJ, Montefiori DC, Haynes BF, Israel ZR, Eldridge JH, Staats HF.
    Vaccine; 2004 Sep 09; 22(27-28):3774-88. PubMed ID: 15315859
    [Abstract] [Full Text] [Related]

  • 17. Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens.
    Bazhan SI, Belavin PA, Seregin SV, Danilyuk NK, Babkina IN, Karpenko LI, Nekrasova NA, Lebedev LR, Ignatyev GM, Agafonov AP, Poryvaeva VA, Aborneva IV, Ilyichev AA.
    Vaccine; 2004 Apr 16; 22(13-14):1672-82. PubMed ID: 15068850
    [Abstract] [Full Text] [Related]

  • 18. Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine.
    De Groot AS, Bishop EA, Khan B, Lally M, Marcon L, Franco J, Mayer KH, Carpenter CC, Martin W.
    Methods; 2004 Dec 16; 34(4):476-87. PubMed ID: 15542374
    [Abstract] [Full Text] [Related]

  • 19. Overcoming original (antigenic) sin.
    Anderson DE, Carlos MP, Nguyen L, Torres JV.
    Clin Immunol; 2001 Nov 16; 101(2):152-7. PubMed ID: 11683574
    [Abstract] [Full Text] [Related]

  • 20. HIV-1 neutralizing antibodies elicited by the candidate CBD1 epitope vaccine react with the conserved caveolin-1 binding motif of viral glycoprotein gp41.
    Rey-Cuillé MA, Svab J, Benferhat R, Krust B, Briand JP, Muller S, Hovanessian AG.
    J Pharm Pharmacol; 2006 Jun 16; 58(6):759-67. PubMed ID: 16734977
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.